Comparing Daptomycin and Vancomycin for MRSA Bloodstream Infections
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
This study is testing whether daptomycin or vancomycin works better for treating bloodstream infections caused by MRSA in patients.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 15 sites (Concord, New South Wales and 14 other locations) |
| Trial ID | NCT06637332 on ClinicalTrials.gov |
What this trial studies
This clinical trial is an open-label randomized controlled trial that aims to compare the effectiveness of two commonly used antibiotics, daptomycin and vancomycin, in treating patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. Participants will be randomly assigned to receive either daptomycin or vancomycin, and their outcomes will be monitored to determine which treatment is more effective. The study is part of a larger adaptive platform trial focused on improving treatment for Staphylococcus aureus infections.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with methicillin-resistant S. aureus bacteremia.
Not a fit: Patients with severe allergies to vancomycin or daptomycin, or those with suspected MRSA pneumonia, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide clearer guidance on the most effective treatment for MRSA bloodstream infections, potentially improving patient outcomes.
How similar studies have performed: Other studies have explored the effectiveness of daptomycin and vancomycin, but this specific comparison in the context of MRSA bacteremia is part of a novel adaptive platform approach.
Eligibility criteria
Show full inclusion / exclusion criteria
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria: Inclusion Criteria: * Methicillin-resistant S. aureus bacteremia Exclusion Criteria: * Severe allergy or non-severe rash to vancomycin or daptomycin * Suspected or confirmed MRSA pneumonia * Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Where this trial is running
Concord, New South Wales and 14 other locations
- Concord Repatriation and General Hospital — Concord, New South Wales, Australia (Recruiting)
- John Hunter Hospital — Newcastle, New South Wales, Australia (Recruiting)
- Westmead Hospital — Westmead, New South Wales, Australia (Recruiting)
- Royal Brisbane and Women's Hospital — Herston, Queensland, Australia (Recruiting)
- Flinders Medical Centre — Bedford Park, South Australia, Australia (Recruiting)
- Box Hill Hospital — Box Hill, Victoria, Australia (Recruiting)
- Monash Medical Campus (Monash Medical Centre + Jesse McPherson Private Hospital) — Clayton, Victoria, Australia (Recruiting)
- Royal Melbourne Hospital — Parkville, Victoria, Australia (Recruiting)
- Fiona Stanley Hospital — Murdoch, Western Australia, Australia (Recruiting)
- Royal Perth Hospital — Perth, Western Australia, Australia (Recruiting)
- University of Alberta Hospital — Edmonton, Alberta, Canada (Recruiting)
- Fraser Health Authority (Surrey Memorial Hospital) — Surrey, British Columbia, Canada (Recruiting)
- Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital) — St. John's, Newfoundland and Labrador, Canada (Recruiting)
- Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital) — Hamilton, Ontario, Canada (Recruiting)
- McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Todd C Lee, MD MPH FIDSA — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Lina Petrella
- Email: lina.petrella@muhc.mcgill.ca
- Phone: 514-934-1934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.